-
The reform of the pharmaceutical industry is intensifying, and the work of the senior management is frequently transferred
Time of Update: 2022-05-24
On March 29, Hualan Biology issued an announcement that the board of directors recently received written resignation reports from the company's senior executives, Wang Qiping, An Wenqi, and Pan Ruowen.
-
Huahai Pharmaceutical's Nebivolol Tablets Obtained FDA Approval Number
Time of Update: 2022-05-24
On April 10, Huahai Pharmaceutical issued an announcement stating that it had received a notification from the US FDA that the company had submitted an abbreviated new drug application for nebivolol tablets to the US FDA (ANDA, that is, the US generic drug application, and the application was approved by the US FDA for review and approval).
-
Multi-pharmaceutical companies signed overseas licensing agreements to accelerate international market layout
Time of Update: 2022-05-24
On the morning of April 7, Harbin Pharmaceutical announced that it has entered into a global external licensing agreement with AstraZeneca to develop and commercialize HBM7022 .
-
Baiji Baiji, Nuocheng Jianhua, Hengrui and other pharmaceutical companies enter the tens of billions of BTK inhibitor market
Time of Update: 2022-05-24
According to relevant data analysis, the global market for BTK inhibitors is growing rapidly and is expected to reach US$11.
Take Nuocheng Jianhua's orelabrutinib as an example, which was approved in China on December 25, 2020 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Two indications for relapsed/refractory mantle cell lymphoma (MCL) .
-
Veru's share price surges over 180% after the success of the new crown oral drug phase III
Time of Update: 2022-05-23
This is a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of sabizabulin in patients with moderate-to-severe COVID-19 at risk of acute respiratory distress syndrome (ARDS) and death .
-
Pfizer's new crown vaccine Comirnaty and oral drug Paxlovid miss first-quarter sales
Time of Update: 2022-05-23
The reason for the downgrade is that the team's latest forecast believes that the sales revenue of Pfizer's new crown oral drug Paxlovid and new crown vaccine Comirnaty will be lower than expected in Q1 this year .
-
U.S. FDA cancels partial clinical suspension of Gilead's CD47 monoclonal antibody
Time of Update: 2022-05-23
Clinical studies evaluating magrolimab in combination with azacitidine for the treatment of MDS and AML will now resume patient enrollment in the United States, according to the latest decision issued by the FDA .
-
Several pharmaceutical companies were fined for selling inferior drugs!
Time of Update: 2022-05-23
In March, an administrative penalty information released by Credit Guangzhou showed that a branch of a large pharmaceutical retail enterprise was fined 100,000 yuan for producing and selling inferior drugs .
-
Since March, pharmaceutical biology is still a hot research field for institutions, and these pharmaceutical companies have received high attention
Time of Update: 2022-05-23
. In response to the future product-related issues that institutions are concerned about, Changchun Hi-Tech stated that in terms of product research and development, the company will actively pay attention to children's nutrition, women's health and other fields according to strategic planning and actual business conditions, and at the same time carry out projects with an international perspective and based on the frontier fields of pharmaceuticals.
-
BeiGene's final response assessment for zanubrutinib achieves primary endpoint superiority over ibrutinib
Time of Update: 2022-05-23
On April 11, BeiGene announced the final response assessment results of the ALPINE study of the global Phase 3 clinical trial of zanubrutinib (Baiyueze®): the independent review committee (IRC) confirmed that in patients with relapsed or refractory (R /R) In adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the BTK inhibitor Baiyueze® (zanubrutinib) demonstrated superior overall response rate (ORR) to ibrutinib ) .
-
Recently, many multinational pharmaceutical companies have made frequent moves!
Time of Update: 2022-05-23
Recently, many multinational pharmaceutical companies, including Takeda Pharmaceuticals, Johnson & Johnson, and Fuji Irvine Biotechnology, have made frequent moves, mainly including merging product lines, building new business experience centers, and innovation cooperation centers .
-
These pharmaceutical companies announced the first financial report after listing, and the word "profit" took the lead!
Time of Update: 2022-05-23
The report shows that the company will achieve operating income of 530 million yuan in 2021, a year-on-year increase of 8.
-
Initiated recruitment orders for talents in the global biopharmaceutical industry in many places, with an annual salary of up to 3 million
Time of Update: 2022-05-23
Among them, in the biopharmaceutical industry, in the high-level talent demand list released this time, there are many positions such as chief commercial officer and dean of biological research institutes provided by Chengdu Pioneer Division, Olin Bio and other companies, with an annual salary of more than 3 million yuan .
-
Senior executives of traditional Chinese medicine companies leave frequently, and more than 6 "leave" in March
Time of Update: 2022-05-23
According to the data, Essence Pharmaceutical is an enterprise mainly engaged in the research and development, production and sales of Chinese patent medicines, APIs, pharmaceutical intermediates and western medicine preparations .
-
The time for the sixth batch of national procurement has been decided in many places, and the reshuffle of the insulin market will begin immediately
Time of Update: 2022-05-23
For example, on April 11, the Hainan Provincial Medical Insurance Bureau issued the "Pre-Notice on the Implementation of the Recent National and Inter-Provincial Alliance Organizations for the Centralized Procurement of Drugs with Volume", stating that Hainan Province is expected to issue the sixth batch of national centralized procurement (insulin) before the end of April.
-
The use of antibiotics in tertiary hospitals is restricted again!
Time of Update: 2022-05-23
The "Notice of the National Health and Health Commission on Further Strengthening the Management of Antimicrobial Drugs to Curb Drug Resistance" (Guowei Medical Letter [2021373]) pointed out that local health administrative departments at all levels should include the rational use of antimicrobial drugs in hospital evaluation, public health Hospital performance assessment, rational drug use assessment and other work, and appropriately increase the assessment weight to play the role of the baton .
-
Domestic pharmaceutical companies have reached a number of license-out transactions, further expanding overseas markets
Time of Update: 2022-05-23
On March 30, Boaoxin Bio announced that it signed a licensing agreement with Pyxis oncology (NASDAQ: PYXS) .
Under the agreement, Pyxis Oncology will receive an exclusive license for the global development and commercialization of Boaoxin BSI-060T, excluding Greater China .
-
Last month, domestic biopharmaceutical companies reached 6 license-in transactions
Time of Update: 2022-05-23
On March 22, 2022, Uray Pharma announced that it has entered into a licensing agreement with Bavarian Nordic, a Danish vaccine company, to acquire the exclusive rights to develop, manufacture and commercialize the Bavarian Nordic Respiratory Syncytial Virus (RSV) vaccine MVA-BN .
-
The independent and controllable biopharmaceutical supply chain has become a trend, and the leading pharmaceutical machine companies have attracted the attention of securities companies
Time of Update: 2022-05-23
The industry expects that the independent and controllable biopharmaceutical supply chain will become a major trend, and the leading pharmaceutical machine companies are expected to benefit in this context .
-
Beijing Municipal People's Government issued a document!
Time of Update: 2022-05-23
Adhere to and improve the basic medical insurance system and policy system that covers the whole people and participates in accordance with the law, employees and urban and rural residents are guaranteed classified protection, benefits are linked to payment, and funds are separately established and accounted for separately .
